Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-546b4f848f-gfk6d Total loading time: 0 Render date: 2023-05-31T18:57:46.674Z Has data issue: false Feature Flags: { "useRatesEcommerce": true } hasContentIssue false

Section VI - Iatrogenic hemorrhagic strokes: anticoagulation-related intracranial hemorrhage

Published online by Cambridge University Press:  20 October 2016

Edited by
Alexander Tsiskaridze ,
Arne Lindgren  and
Adnan I. Qureshi
Alexander Tsiskaridze
Affiliation:
Sarajishvili Institute of Neurology, Tblisi State University, Georgia
Arne Lindgren
Affiliation:
Department of Neurology, University Hospital Lund, Sweden
Adnan I. Qureshi
Affiliation:
Department of Neurology, University of Minnesota
Get access
Type
Chapter
Information
Treatment-Related Stroke
Including Iatrogenic and In-Hospital Strokes
 , pp. 185 - 202
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

Fang, M C, Chang, Y, Hylek, E M, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004; 141(10):745–52.
Fang, M C, Go, A S, Chang, Y, et al. Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke. 2012; 43(7):1795–9.
DiMarco, J P, Flaker, G, Waldo, A L, et al. AFFIRM Investigators. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: Observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005; 149(4):650–6.
Ghate, S R, Biskupiak, J, Ye, X, Kwong, W J, Brixner, D I. All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation. J Manag Care Pharm. 2011; 17(9):672–84.
Mattle, H, Kohler, S, Huber, P, Rohner, M, Steinsiepe, K F. Anticoagulation-related intracranial extracerebral haemorrhage. J Neurol Neurosurg Psychiatry. 1989; 52(7): 829–37.
Baechli, H, Nordmann, A, Bucher, H C, Gratzl, O. Demographics and prevalent risk factors of chronic subdural haematoma: results of a large single-center cohort study. Neurosurg Rev. 2004; 27(4):263–6.
Mant, J, Hobbs, F D, Fletcher, K, et al. BAFTA investigators. Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A randomised controlled trial. Lancet. 2007; 370(9586):493–503.
Gulløv, A L, Koefoed, B G, Petersen, P. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation. Arch Intern Med. 1999; 159(12):1322–8.
Hart, R G, Benavente, O, Pearce, L A. Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: A meta-analysis and hypothesis. Cerebrovasc Dis. 1999; 9(4):215–17.
Bond, A J, Molnar, F J, Li, M, Mackey, M, Man-Son-Hing, M. The risk of hemorrhagic complications in hospital in-patients who fall while receiving antithrombotic therapy. Thromb J. 2005; 3(1):1.
Airaksinen, K E, Suurmunne, H, Porela, P, et al. Usefulness of outpatient bleeding risk index to predict bleeding complications in patients with long-term oral anticoagulation undergoing coronary stenting. Am J Cardiol. 2010; 106(2):175–9. Epub 2010 Jun 9.
Ruíz-Giménez, N, Suárez, C, González, R, et al. RIETE Investigators. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008; 100(1):26–31.
Gage, B F, Yan, Y, Milligan, P E, et al. Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006; 151(3):713–19.
Lip, G Y, Frison, L, Halperin, J L, Lane, D A. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: The HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011; 57(2):173–80.
Loewen, P, Dahri, K. Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules. Ann Hematol. 2011; 90(10):1191–200.
Fang, M C, Go, A S, Chang, Y, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007; 120(8):700–5.
Gomez, P A, Lobato, R D, Ortega, J M, de la Cruz, J. Mild head injury: Differences in prognosis among patients with a Glasgow Coma Scale score of 13 to 15 and analysis of factors associated with abnormal CT findings. Br J Neurosurg. 1996; 10:453–60.
Servadei, F, Teasdale, G, Merry, G. Defining acute mild head injury in adults: A proposal based on prognostic factors, diagnosis, and management. J Neurotrauma. 2001; 18:657–64.
Vos, P E, Battistin, L, Birbamer, G, et al. EFNS guideline on mild traumatic brain injury: Report of an EFNS task force. Eur J Neurol. 2002; 9:207–19.
Rust, T, Kiemer, N, Erasmus, A. Chronic subdural haematomas and anticoagulation or anti-thrombotic therapy. J Clin Neurosci. 2006; 13(8):823–7.
Baechli, H, Nordmann, A, Bucher, H C, Gratzl, O. Demographics and prevalent risk factors of chronic subdural haematoma: results of a large single-center cohort study. Neurosurg Rev. 2004; 27(4):263–6.
Lindvall, P, Koskinen, L O. Anticoagulants and antiplatelet agents and the risk of development and recurrence of chronic subdural haematomas. J Clin Neurosci. 2009; 16(10):1287–90.
Forster, M T, Mathé, A K, Senft, C, et al. The influence of preoperative anticoagulation on outcome and quality of life after surgical treatment of chronic subdural hematoma. J Clin Neurosci. 2010; 17(8):975–9.
Hanley, J P. Warfarin reversal. J Clin Pathol. 2004; 57(11):1132–9.
Ducruet, A F, Grobelny, B T, Zacharia, B E, et al. The surgical management of chronic subdural hematoma. Neurosurg Rev. 2012; 35(2):155–69.
Robinson, M T, Rabinstein, A A, Meschia, J F, Freeman, W D. Safety of recombinant activated factor VII in patients with warfarin-associated hemorrhages of the central nervous system. Stroke. 2010; 41(7):1459–63.
Senft, C, Schuster, T, Forster, M T, Seifert, V, Gerlach, R. Management and outcome of patients with acute traumatic subdural hematomas and pre-injury oral anticoagulation therapy. Neurol Res. 2009; 31(10):1012–18.
Panczykowski, D M, Okonkwo, D O. Premorbid oral antithrombotic therapy and risk for reaccumulation, reoperation, and mortality in acute subdural hematomas. J Neurosurg. 2011; 114(1):47–52.
Hart, R G, Diener, H C, Yang, S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke. 2012; 43(6):1511–17.
Tarlov, N, Norbash, A M, Nguyen, T N. The safety of anticoagulation in patients with intracranial aneurysms. J Neurointerv Surg. 2012, Jun 7.
Metso, T M, Metso, A J, Helenius, J, et al. Prognosis and safety of anticoagulation in intracranial artery dissections in adults. Stroke. 2007; 38(6):1837–42.
Byrnes, M C, Irwin, E, Roach, R, et al. Therapeutic anticoagulation can be safely accomplished in selected patients with traumatic intracranial hemorrhage. World J Emerg Surg. 2012; 7(1):25.
Patel, M R, Mahaffey, K W, Garg, J, et al. The ROCKET Steering Committee for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365:883–91.

References

Ogilvie, I M, Newton, N, Welner, S A, Cowell, W, Lip, G Y H. Underuse of oral anticoagulants in atrial fibrillation: A systematic review. Am J Med. 2010; 123:638–45.
Shroff, G R, Solid, C A, Herzog, C A. Temporal trends in ischemic stroke and anticoagulation therapy among Medicare patients with atrial fibrillation: A 15-year perspective (1992–2007). JAMA Intern Med. 2013; 173:159–60.
Connolly, S J, Ezekowitz, M D, Yusuf, S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:1139–51.
Patel, M R, Mahaffey, K W, Garg, J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365:883–91.
Granger, C B, Alexander, J H, McMurray, J J V, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365:981–92.
Connolly, S J, Eikelboom, J, Joyner, C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011; 364:806–17.
Giugliano, R P, Ruff, C T, Rost, N S, et al. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48. Stroke. 2014; 45:2372–8.
Connolly, S J, Wallentin, L, Ezekowitz, M D, et al. The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study. Circulation. 2013; 128:237–43.
Hart, R G, Diener, H C, Yang, S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: The RE-LY trial. Stroke. 2012; 43:1511–17.
Hankey, G J, Stevens, S R, Piccini, J P, et al. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: The rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke. 2014; 45:1304–12.
Ruff, C T, Giugliano, R P, Braunwald, E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014; 383:955–62.
Gage, B F, Yan, Y, Milligan, P E, Waterman, A D, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006; 151:713–19.
Pisters, R, Lane, D A, Nieuwlaat, R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest. 2010; 138:1093–100.
Fang, M C, Go, A S, Chang, Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study. J Am Coll Cardiol. 2011; 58:395–401.
Apostolakis, S, Lane, D A, Guo, Y, Buller, H, Lip, G Y. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: The AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol. 2012; 60:861–7.
Hart, R G, Boop, B S, Anderson, D C. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke. 1995; 26:1471–7.
Fang, M C, Go, A S, Chang, Y, Hylek, E M, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007; 120:700–5.
Steiner, T, Kaste, M, Forsting, M, et al. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Recommendations for the management of intracranial haemorrhage – part I: Spontaneous intracerebral haemorrhage. Cerebrovasc Dis. 2006; 22:294–316.
Själander, A, Engström, G, Berntorp, E, Svensson, P. Risk of haemorrhagic stroke in patients with oral anticoagulation compared with the general population. J Intern Med. 2003; 254:434–8.
Go, A S, Hylek, E M, Phillips, K A, Chang, Y, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 285:2370–5.
Franke, C L, de Jonge, J, van Swieten, J C, Op de Coul, A A, van Gijn, J. Intracerebral hematomas during anticoagulant treatment. Stroke. 1990; 21:726–30.
Flibotte, J J, Hagan, N, O’Donnell, J, Greenberg, S M, Rosand, J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004; 63:1059–64.
Sacco, S, Marini, C, Toni, D, Olivieri, L, Carolei, A. Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry. Stroke. 2009; 40:394–9.
Horstmann, S, Rizos, T, Lauseker, M, et al. Intracerebral hemorrhage during anticoagulation with vitamin K antagonists: a consecutive observational study. J Neurol. 2013; 260:2046–51.
Lip, G Y, Andreotti, F, Fauchier, L, et al. Bleeding risk assessment and management in atrial fibrillation patients: A position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace. 2011; 13:723–46.
Petitti, D, Strom, B, Melmon, K. Duration of warfarin anticoagulation therapy and the probabilities or recurrent thromboembolism and hemorrhage. Am J Med. 1986; 81:255–9.
Fihn, S D, McDonnel, M, Martin, D, et al. Warfarin Optimized Outpatient Follow-up Study Group. Risk factors for complications of chronic anticoagulation: A multicenter study. Ann Intern Med. 1993; 118:511–20.
Palareti, G, Leali, N, Coccheri, S, et al. Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT). Lancet. 1996; 348:423–8.
Landefeld, C S, Goldman, L. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy. Am J Med. 1989; 87:144–52.
Hart, R G, Tonarelli, S B, Pearce, L A. Avoiding central nervous system bleeding during antithrombotic therapy: Recent data and ideas. Stroke. 2005; 36:1588–93.
Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994; 154:1449–57.
SPAF-Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke prevention in atrial fibrillation II study. Lancet. 1994; 343:687–91.
Olsson, S B. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomised controlled trial. Lancet. 2003; 362:1691–8.
Albers, G W, Diener, H C, Frison, L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005; 293:690–8.
Di Marco, J P, Flaker, G, Waldo, A L, et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: Observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005; 149:650–6.
Landefeld, C S, Goldman, L. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy. Am J Med. 1989; 87:144–52.
van der Meer, F J, Rosendaal, F R, Vandenbroucke, J P, Briet, E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med. 1993; 153:1557–62.
Steffensen, F H, Kristensen, K, Ejlersen, E, Dahlerup, J F, Sorensen, H T. Major haemorrhagic complications during oral anticoagulant therapy in a Danish population-based cohort. J Intern Med. 1997; 242:497–503.
Beyth, R J, Quinn, L M, Landefeld, C S. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998; 105:91–9.
Go, A S, Hylek, E M, Chang, Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: How well do randomized trials translate into clinical practice? JAMA. 2003; 290:2685–92.
Hylek, E M, Evans-Molina, C, Shea, C, Henault, L E, Regan, S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007; 115:2689–96.
Poli, D, Antonucci, E, Grifoni, E, et al. Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J Am Coll Cardiol. 2009; 54:999–1002.
Vandenbroucke, J P. Why do the results of randomised and observational studies differ? BMJ. 2011; 343:d7020.
Charidimou, A, Shakeshaft, C, Werring, D J. Cerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage risk. Front Neurol. 2012; 19:133.
Larsen, T B, Rasmussen, L H, Skjøth, F, Due, K M, et al. Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: A prospective nationwide cohort study. J Am Coll Cardiol. 2013; 61:2264–73.
Southworth, M R, Reichman, M E, Unger, E F. Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013; 368:1272–4.
Hankey, G J. Intracranial hemorrhage and novel anticoagulants for atrial fibrillation: What have we learned? Curr Cardiol Rep. 2014; 16:480.
Wintzen, A R, De Jonge, H, Loeliger, E A, Botts, G T A M. The risk of intracerebral hemorrhage during oral anticoagulant treatment: A population study. Ann Neurol. 1984; 16:533–8.
Fisher, C M. Pathological observations in hypertensive cerebral hemorrhage. J Neuropathol Exp Neurol. 1971; 30:536–50.
Brouwers, H B, Goldstein, J N, Romero, J M, Rosand, J. Clinical applications of the computed tomography angiography spot sign in acute intracerebral hemorrhage: A review. Stroke. 2012; 43:3427–32.
Demchuk, A M, Dowlatshahi, D, Rodriguez-Luna, D, et al. PREDICT/Sunnybrook ICH CTA study group. Prediction of hematoma growth and outcome in patients with intracerebral haemorrhage using the CT-angiography spot sign (PREDICT): A prospective observational study. Lancet Neurol. 2012; 11:307–14.
Delgado Almandoz, J E, Yoo, A J, Stone, M J, et al. Systematic characterization of the computed tomography angiography spot sign in primary intracerebral hemorrhage identifies patients at highest risk for hematoma expansion: The spot sign score. Stroke. 2009; 40:2994–3000.
Brouwers, H B, Biffi, A, McNamara, K A, et al. Apolipoprotein E genotype is associated with CT angiography spot sign in lobar intracerebral hemorrhage. Stroke. 2012; 43:2120–5.
Brouwers, H B, Greenberg, S M. Hematoma expansion following acute intracerebral hemorrhage. Cerebrovasc Dis. 2013; 35:195–201.
Greenberg, C H, Frosch, M P, Goldstein, J N, Rosand, J, Greenberg, S M. Modeling intracerebral hemorrhage growth and response to anticoagulation. PLoS One. 2012; 7:e48458.
Grysiewicz, R, Gorelick, P B. Incidence, mortality, and risk factors for oral anticoagulant-associated intracranial hemorrhage in patients with atrial fibrillation. J Stroke Cerebrovasc Dis. 2014; 23:2479–88.
Hylek, E M, Singer, D E. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994; 120:897–902.
Fang, M C, Chang, Y, Hylek, E M, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004; 16:745–52.
Stroke Prevention in Atrial Fibrillation (SPAF) II Study. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation. Lancet. 1994; 343:687–91.
Birman-Deych, E, Radford, M J, Nilasena, D S, Gage, B F. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke. 2006; 37:1070–4.
Shen, A Y, Yao, J F, Brar, S S, Jorgensen, M B, Chen, W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007; 50:309–15.
Hylek, E M, Go, A S, Chang, Y, Jensvold, N G, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003; 349:1019–26.
Berwaerts, J, Webster, J. Analysis of risk factors involved in oral-anticoagulant-related intracranial haemorrhages. QJM. 2000; 93:513–21.
Fric-Shamji, E C, Shamji, M F, Cole, J, Benoit, B G. Modifiable risk factors for intracerebral hemorrhage: study of anticoagulated patients. Can Fam Physician. 2008; 54:1138–9.
The Stroke Prevention In Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol. 1997; 42:857–65.
Revesz, T, Holton, J L, Lashley, T, et al. Sporadic and familial cerebral amyloid angiopathies. Brain Pathol. 2002; 12:343–57.
Greenberg, S M, Rebeck, G W, Vonsattel, J P, Gomez-Isla, T, Hyman, B T. Apolipo-protein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol. 1995; 38:254–9.
Nicoll, J A, Burnett, C, Love, S, et al. High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann Neurol. 1997; 41:716–21.
Biffi, A, Sonni, A, Anderson, C D, et al. Variants at APOE influence risk of deep and lobar intracerebral hemorrhage. Ann Neurol. 2010; 68:934–43.
Rosand, J, Hylek, E M, O’Donnell, H C, Greenberg, S M. Warfarin-associated hemorrhage and cerebral amyloid angiopathy: A genetic and pathologic study. Neurology. 2000; 55:947.
Melo, T P, Bogousslavsky, J, Regli, F, Janzer, R. Fatal hemorrhage during anticoagulation of cardioembolic infarction: Role of cerebral amyloid angiopathy. Eur Neurol. 1993: 33:9–12.
Flockhart, D A, O’Kane, D, Williams, M S, et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med. 2008; 10:139–50.
Stehle, S, Kirchheiner, J, Lazar, A, Fuhr, U. Pharmacogenetics of oral anticoagulants: A basis for dose individualization. Clin Pharmacokinet. 2008; 47:565–94.
Higashi, M K, Veenstra, D L, Kondo, L M, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002; 287:1690–8.
Rybak, I, Ehle, M, Buckley, L, Fanikos, J. Efficacy and safety of novel anticoagulants compared with established agents. Ther Adv Hematol. 2011; 2:175–95.
Mega, J L, Walker, J R, Ruff, C T, et al. Genetics and the clinical response to warfarin and edoxaban: Findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015; 385:2280–7.
Shireman, T I, Howard, P A, Kresowik, T F, Ellerbeck, E F. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke. 2004; 35:2362–7.
Gouw, A A, Seewann, A, Van Der Flier, W M, et al. Heterogeneity of small vessel disease: A systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatr. 2010; 82:126–35.
Schmidt, R, Grazer, A, Enzinger, C, et al. MRI-detected white matter lesions: Do they really matter? J Neural Transm. 2011; 118:673–81.
Gorter, J W. Major bleeding during anticoagulation after cerebral ischemia: Patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. Neurology. 1999; 53:1319–27.
Smith, E E, Rosand, J, Knudsen, K A, Hylek, E M, Greenberg, S M. Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology. 2002; 59:193–7.
Greenberg, S M, Vernooij, M W, Cordonnier, C, et al. Cerebral microbleeds: A guide to detection and interpretation. Lancet Neurol. 2009; 8:165–74.
Lee, S H, Ryu, W S, Roh, J K. Cerebral microbleeds are a risk factor for warfarin-related intracerebral hemorrhage. Neurology. 2009; 72:171–6.
Ueno, H, Naka, H, Ohshita, T, et al. Association between cerebral microbleeds on T2*-weighted MR images and recurrent hemorrhagic stroke in patients treated with warfarin following ischemic stroke. Am J Neuroradiol. 2008; 29:1483–6.
Lovelock, C E, Cordonnier, C, Naka, H, et al. Edinburgh Stroke Study Group. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies. Stroke. 2010; 41:1222–8.
Charidimou, A, Peeters, A P, Jäger, R, et al. Cortical superficial siderosis and intracerebral hemorrhage risk in cerebral amyloid angiopathy. Neurology. 2013; 81:1666–73.
Kidwell, C S, Chalela, J A, Saver, J L, et al. Comparison of MRI and CT for detection of acute intracerebral hemorrhage. JAMA. 2004; 292:1823–30.
Greenberg, S M, Eng, J A, Ning, M, Smith, E E, Rosand, J. Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage. Stroke. 2004; 35:1415–20.
Cucchiara, B, Messe, S, Sansing, L, Kasner, S, Lyden, P; CHANT Investigators. Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke. 2008; 39:2993–6.
Flaherty, M L, Tao, H, Haverbusch, M, et al. Warfarin use leads to larger intracerebral hematomas. Neurology. 2008; 71:1084–9.
Sheth, K N, Cushing, T A, Wendell, L, et al. Comparison of hematoma shape and volume estimates in warfarin versus non-warfarin-related intracerebral hemorrhage. Neurocrit Care. 2010; 12:30–4.
Levine, J M, Snider, R, Finkelstein, D, et al. Early edema in warfarin-related intracerebral hemorrhage. Neurocrit Care. 2007; 7:58–63.
Biffi, A, Battey, T W, Ayres, A M, et al. Warfarin-related intraventricular hemorrhage: imaging and outcome. Neurology. 2011; 15:1840–6.
Kase, C S, Robinson, R K, Stein, R W, et al. Anticoagulant-related intracerebral hemorrhage. Neurology. 1985; 35:943–8.
Toyoda, K, Okada, Y, Ibayashi, S, et al. Antithrombotic therapy and predilection for cerebellar hemorrhage. Cerebrovasc Dis. 2007; 23:109.
Brott, T, Broderick, J, Kothari, R, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997; 28:1–5.
Balami, J S, Buchan, A M. Complications of intracerebral haemorrhage. Lancet Neurol. 2012; 11:101–18.
Veltkamp, R, Rizos, T, Horstmann, S. Intracerebral bleeding in patients on antithrombotic agents. Semin Thromb Hemost. 2013; 39:963–71.
Sjöblom, L, Hårdemark, H G, Lindgren, A, et al. Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: A Swedish multicenter study. Stroke. 2001; 32:2567–74.
Rosand, J, Eckman, M H, Knudsen, K A, Singer, D E, Greenberg, S M. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med. 2004; 164:880–4.
Zubkov, A Y, Mandrekar, J N, Claassen, D O, et al. Predictors of outcome in warfarin-related intracerebral hemorrhage. Arch Neurol. 2008; 65:1320–5.

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×